Rare genetic metabolic disorders
Ultragenyx Pharmaceutical Inc. funds clinical research in glycogen storage disease type Ia, ornithine transcarbamylase deficiency, and long-chain fatty acid oxidation disorders, with a strong focus on restoring metabolic control and reducing disease burden in inherited conditions affecting energy and ammonia handling.
- Glycogen storage disease type Ia
- Ornithine transcarbamylase deficiency
- Long-chain fatty acid oxidation disorders
Its research portfolio also includes Wilson disease, reflecting interest in disorders of copper regulation and broader inborn errors of metabolism.
Neurological and neurodevelopmental conditions
The sponsor supports studies in Angelman syndrome and mucopolysaccharidosis type IIIA, with attention to cognitive function, neurological impairment, and long-term disease management in genetic conditions that affect development and the nervous system.
- Angelman syndrome
- Mucopolysaccharidosis type IIIA
These programs address both symptomatic impact and durable treatment effects in rare inherited disorders with central nervous system involvement.
Bone fragility and skeletal disease
Ultragenyx also funds clinical work in osteogenesis imperfecta, a rare skeletal disorder marked by bone fragility and recurrent fractures, with research centered on fracture reduction and improved skeletal outcomes.
- Osteogenesis imperfecta
- Brittle bone syndrome
This area highlights sustained interest in pediatric and lifelong management of inherited bone disease.
Gene therapy and long-term follow-up
A substantial part of the sponsor’s clinical activity involves gene therapy and extended monitoring in rare diseases, including inherited metabolic, neurological, and skeletal disorders. The portfolio includes studies designed to assess lasting safety, tolerability, and disease control after treatment in diverse genetic conditions.
- Gene therapy
- Long-term safety
- Inherited rare disease care
Research activity spans multiple countries and collaborating sites, supporting clinical development across several distinct rare disease programs.
